Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NEW YORK, March 04, 2016 -- Remedy Pharmaceuticals, a privately-held, pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), which took place on March 2, 2016.
“Our End-of-Phase 2 meeting was a decisive milestone for the Company as we advance the clinical development of CIRARA™,” states Sven Jacobson, Chief Executive Officer of Remedy Pharmaceuticals. “We are pleased with the FDA’s guidance on our Phase 3 trial design in patients with large hemispheric stroke and we look forward to initiating the study as quickly as possible.”
“There is a major unmet medical need to treat CNS-related edema,” said David Geliebter, Executive Chairman of Remedy Pharmaceuticals. “The encouraging data from our Phase 2 studies suggest CIRARA has the potential to reduce mortality and improve functional outcomes for patients with large hemispheric strokes. We’re now one step closer to achieving that goal.”
ABOUT CIRARA
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, discovered by University of Maryland neurosurgeon Dr. J. Marc Simard. CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ measured phase dosing technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 [email protected] Investors Lee Roth / Tram Bui, The Ruth Group 646-536-7012 / 646-536-7035 [email protected] / [email protected] Media Kirsten Thomas, The Ruth Group 508-280-6592 [email protected]
